What is Adaptimmune Therapeutics Plc - ADR Annual Revenue?

Adaptimmune Therapeutics Plc - ADR Annual Revenue rose 195.34%, in the last year to $178.03 M. Its sector's average revenue growth for the last fiscal year was 7.49%.

What is Adaptimmune Therapeutics Plc - ADR Annual Net Profit?

Adaptimmune Therapeutics Plc - ADR Annual Net Profit rose 37.81% in the last year to $70.81 M. Its sector's average net profit growth for the last fiscal year was -32.47%.

What is Adaptimmune Therapeutics Plc - ADR Price to Earning Ratio?

Adaptimmune Therapeutics Plc - ADR Price to Earning Ratio is -1.01, which is negative.

What is Adaptimmune Therapeutics Plc - ADR Stock Price?

Adaptimmune Therapeutics Plc - ADR Stock Price fell 75% and underperformed its sector by 86.38% in the past year.

What is Adaptimmune Therapeutics Plc - ADR Quarterly Revenue?

Adaptimmune Therapeutics Plc - ADR Quarterly Revenue rose 1,294.81% YoY to $3.22 M. Its sector's average revenue growth YoY for the quarter was 5.79%.

What is Adaptimmune Therapeutics Plc - ADR Quarterly Net profit?

Adaptimmune Therapeutics Plc - ADR Quarterly Net profit fell 54.88% YoY to $74.22 M. Its sector's average net profit growth YoY for the quarter was -41.99%.

What is Adaptimmune Therapeutics Plc - ADR Debt to Equity Ratio?

Adaptimmune Therapeutics Plc - ADR Debt to Equity Ratio of 6.26 is higher than 1. This implies that company assets are financed through debt.

What is Adaptimmune Therapeutics Plc - ADR Return on Equity(ROE)?

Adaptimmune Therapeutics Plc - ADR Return on Equity(ROE) for the last financial year was -275.74%, less than 10%, indicating an inefficient use of shareholder's capital to generate profit.

What is Adaptimmune Therapeutics Plc - ADR Mutual Fund Holding?

Adaptimmune Therapeutics Plc - ADR Mutual Fund Holding increased by 0.01% in the last quarter to 5.35.

What is Adaptimmune Therapeutics Plc - ADR Promoter Share Holding?

Adaptimmune Therapeutics Plc - ADR Promoter Share Holding decreased by 0.01% in the most recent quarter to 0.06%.

What is Adaptimmune Therapeutics Plc - ADR Interest Coverage Ratio?

Adaptimmune Therapeutics Plc - ADR Interest Coverage Ratio is -19.08, lesser than one. This means that it is unable to pay interests with its earnings (EBIT).

What is Adaptimmune Therapeutics Plc - ADR Institutional Holding?

Adaptimmune Therapeutics Plc - ADR Institutional Holding decreased by 0.04% in the last quarter to 48.25.

How is the Adaptimmune Therapeutics Plc - ADR today?

The Adaptimmune Therapeutics Plc - ADR today is trading in the green, up by 3.85% at 0.27.

How has Adaptimmune Therapeutics Plc - ADR performed historically?

The Adaptimmune Therapeutics Plc - ADR is currently trading up 3.85% on an intraday basis in the past week the index rose 12.50%. The index has been down -54.24% in the past quarter and fell -75.00% in the past year. You can view this in the overview section.

Adaptimmune Therapeutics Plc - ADR XNAS: ADAP

Adaptimmune Therapeutics Plc - ADR Live Share Price Today, Share Analysis and Chart

Name: Adaptimmune Therapeutics Plc - ADR: Is Infosys Ltd. worth buying?
Item: Adaptimmune Therapeutics Plc - ADR
Rating: 0.968375125
Author: Trendlyne DVM scores

Weak Stock

Download real time

0.27 0.01 (3.85%)

81.76% Fall from 52W High

432.1K XNAS Volume

XNAS 24 Apr, 2025 5:30 PM (EDT)

Adaptimmune Therapeutics P... Key Metrics

My Metrics

Select

Market Capitalization Below industry Median Unavailable in chosen country	71.2
PE TTM Negative PE TTM Unavailable in chosen country	-1
Price to Book High in industry Unavailable in chosen country	5.9
Institutional holding current Qtr % Below industry Median Unavailable in chosen country	48.3
Revenue Growth Qtr YoY % High in industry Unavailable in chosen country	1,294.8
Operating Revenue growth TTM % High in industry Unavailable in chosen country	195.3
Net Profit Qtr Growth YoY % Negative Net Profit Qtr Growth YoY % Unavailable in chosen country	-54.9
Net Profit TTM Growth % Below industry Median Unavailable in chosen country	37.8
Operating Profit Margin Qtr % Negative Operating Profit Margin Qtr % Unavailable in chosen country	-1,774.3
Operating Profit Margin TTM % Negative Operating Profit Margin TTM % Unavailable in chosen country	-29.4
Piotroski Score High in industry Unavailable in chosen country	3
Rel Perf vs Sector quarter% Unavailable in chosen country	-54.8
ROE Annual % Negative ROE Annual % Unavailable in chosen country	-275.7
RoA Annual % Negative RoA Annual % Unavailable in chosen country	-26.8

All financials are in USD Million and price data in USD

Low Financial Strength

16.7 / 100

Expensive Valuation

18.7 / 100

Technically Bearish

25.5 / 100

Weak Stock These stocks are the ones with poor quality, financials and technicals. This indicates that investors should be highly watchful with these stocks. View Similar Embed DVM

1Yr Price target upside is 533%

8 analysts

Check Before You Buy

Check P/E Buy Sell Zone

This stock has negative PE

Adaptimmune Therapeutics P... Stock Price Analysis

Day Price Range 3.8% 1 Day return Unavailable in chosen country	0.3 (LTP) 0.30.3 LowHigh
Week Price Range 12.5% 1 Week return Unavailable in chosen country	0.3 (LTP) 0.20.3 LowHigh
Month Price Range -3.6% 1 Month return Unavailable in chosen country	0.3 (LTP) 0.20.3 LowHigh
52 Week Price Range -75.0% 1 Year return Unavailable in chosen country	0.3 (LTP) 0.21.5 LowHigh

View full Share Price History

Adaptimmune Therapeutics P... Live Price Chart

Switch to TradingView

Fetching data ...

Forecaster - Analyst Share Price Target and Estimates

Miss

Adaptimmune Therapeutics Plc - ADR's Revenue was lower than average estimate 2 times in past 3 years

EPS forecast

QUARTER
ANNUAL

Current EPS

-0.3

Avg. Estimate

-0.4

Low Estimate

-0.6

High Estimate

-0.1

Current EPS

Avg. Estimate

Consensus Recommendation

8 ANALYST Recommendations

BUY

The consensus recommendation from 8 analysts for Adaptimmune Therapeutics Plc - ADR is BUY

Forecaster is a Premium Feature

You need to upgrade your subscription plan to access this feature

Upgrade Now

Adaptimmune Therapeutics P... Stock Analysis

Adaptimmune Therapeutics P... stock analysis with key metrics, changes, and trends.

Adaptimmune Therapeutics P... Metric	VALUE	CHANGE %	TREND	ANALYSIS
Annual Revenue	$178.03 M	195.34%	positive	Annual Revenue rose 195.34%, in the last year to $178.03 M. Its sector's average revenue growth for the last fiscal year was 7.49%.
Annual Net Profit	$70.81 M	37.81%	positive	Annual Net Profit rose 37.81% in the last year to $70.81 M. Its sector's average net profit growth for the last fiscal year was -32.47%.
Price to Earning Ratio	-1.01	-	negative	Price to Earning Ratio is -1.01, which is negative.
Stock Price	$0.27	-75%	negative	Stock Price fell 75% and underperformed its sector by 86.38% in the past year.
Quarterly Revenue	$3.22 M	1294.81%	positive	Quarterly Revenue rose 1,294.81% YoY to $3.22 M. Its sector's average revenue growth YoY for the quarter was 5.79%.
Quarterly Net profit	$74.22 M	54.88%	negative	Quarterly Net profit fell 54.88% YoY to $74.22 M. Its sector's average net profit growth YoY for the quarter was -41.99%.
Debt to Equity Ratio	6.26	-	negative	Debt to Equity Ratio of 6.26 is higher than 1. This implies that company assets are financed through debt.
Return on Equity(ROE)	-275.74 %	-275.74%	negative	Return on Equity(ROE) for the last financial year was -275.74%, less than 10%, indicating an inefficient use of shareholder's capital to generate profit.
Mutual Fund Holding	5.35 %	0.01%	positive	Mutual Fund Holding increased by 0.01% in the last quarter to 5.35.
Promoter Share Holding	0.06 %	-0.01%	negative	Promoter Share Holding decreased by 0.01% in the most recent quarter to 0.06%.
Interest Coverage Ratio	-19.08	-	negative	Interest Coverage Ratio is -19.08, lesser than one. This means that it is unable to pay interests with its earnings (EBIT).
Institutional Holding	48.25 %	-0.04%	negative	Institutional Holding decreased by 0.04% in the last quarter to 48.25.

VIEW LESS

Loading data..

Adaptimmune Therapeutics Plc - ADR - Company Profile

What does Adaptimmune Therapeutics Plc - ADR do?

Adaptimmune Therapeutics PLC is a commercial-stage biopharmaceutical company working to redefine the treatment of solid tumor cancers with cell therapies. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A4 SPEAR T-cell therapy, NY-ESO SPEAR T-cell, CD70, and others for multiple cancer types.

Gross Remuneration

2024

Gross Remuneration

Year

Adaptimmune Therapeutics Plc - ADR Live Share Price Today, Share Analysis and Chart

81.76% Fall from 52W High

Adaptimmune Therapeutics P... Key Metrics

Market Capitalization

PE TTM

Price to Book

Institutional holding current Qtr %

Revenue Growth Qtr YoY %

Operating Revenue growth TTM %

Net Profit Qtr Growth YoY %

Net Profit TTM Growth %

Operating Profit Margin Qtr %

Operating Profit Margin TTM %

Piotroski Score

Rel Perf vs Sector quarter%

ROE Annual %

RoA Annual %

SWOT Analysis

Check Before You Buy

Check P/E Buy Sell Zone

Adaptimmune Therapeutics P... Stock Price Analysis

Day Price Range

Week Price Range

Month Price Range

52 Week Price Range

Adaptimmune Therapeutics P... Live Price Chart

Forecaster - Analyst Share Price Target and Estimates

Revenue forecast

Adaptimmune Therapeutics Plc - ADR's Revenue was lower than average estimate 2 times in past 3 years

EPS forecast

Consensus Recommendation

The consensus recommendation from 8 analysts for Adaptimmune Therapeutics Plc - ADR is BUY

Adaptimmune Therapeutics P... Stock Analysis

Adaptimmune Therapeutics P... stock analysis with key metrics, changes, and trends.

Annual Revenue rose 195.34%, in the last year to $178.03 M. Its sector's average revenue growth for the last fiscal year was 7.49%.

Annual Net Profit rose 37.81% in the last year to $70.81 M. Its sector's average net profit growth for the last fiscal year was -32.47%.

Price to Earning Ratio is -1.01, which is negative.

Stock Price fell 75% and underperformed its sector by 86.38% in the past year.

Quarterly Revenue rose 1,294.81% YoY to $3.22 M. Its sector's average revenue growth YoY for the quarter was 5.79%.

Quarterly Net profit fell 54.88% YoY to $74.22 M. Its sector's average net profit growth YoY for the quarter was -41.99%.

Debt to Equity Ratio of 6.26 is higher than 1. This implies that company assets are financed through debt.

Return on Equity(ROE) for the last financial year was -275.74%, less than 10%, indicating an inefficient use of shareholder's capital to generate profit.

Mutual Fund Holding increased by 0.01% in the last quarter to 5.35.

Promoter Share Holding decreased by 0.01% in the most recent quarter to 0.06%.

Interest Coverage Ratio is -19.08, lesser than one. This means that it is unable to pay interests with its earnings (EBIT).

Institutional Holding decreased by 0.04% in the last quarter to 48.25.

Adaptimmune Therapeutics Plc - ADR - Company Profile

What does Adaptimmune Therapeutics Plc - ADR do?

Adaptimmune Therapeutics Plc - ADR Management structure

Mr. Adrian Rawcliffe

Director and Chief Executive Officer

Mr. Gavin Hilary James Wood

Chief Financial Officer and Principal Accounting Officer

Dr. Helen Tayton-Martin, PhD

Chief Business and Strategy Officer

Ms. Cintia Piccina

Chief Commercial Officer

Adaptimmune Therapeutics Plc - ADR Board of directors

Mr. Adrian Rawcliffe

Director and Chief Executive Officer

Dr. Andrew R. Allen, M.D.,PhD

Independent Director

Dr. Kristen M. Hege, M.D.

Independent Director

Mr. David M. Mott

Chairman of the Board

Mr. Lawrence M. Alleva

Independent Director

Dr. Garry E. Menzel, PhD

Independent Director

Adaptimmune Therapeutics Plc - ADR FAQ

How is Adaptimmune Therapeutics Plc - ADR today?

Adaptimmune Therapeutics Plc - ADR today is trading in the green, and is up by 3.85% at 0.27.

How has Adaptimmune Therapeutics Plc - ADR performed historically?

Adaptimmune Therapeutics Plc - ADR is currently trading up 3.85% on an intraday basis. In the past week the stock rose 12.50%. stock has been down -54.24% in the past quarter and fell -75.00% in the past year. You can view this in the overview section.